- Home
- NCZ vs DMAC Comparison
NCZ vs DMAC Comparison
Compare NCZ & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- DMAC
- Stock Information
- Founded
- NCZ 2003
- DMAC 2000
- Country
- NCZ United States
- DMAC United States
- Employees
- NCZ N/A
- DMAC N/A
- Industry
- NCZ Finance Companies
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- DMAC Health Care
- Exchange
- NCZ Nasdaq
- DMAC Nasdaq
- Market Cap
- NCZ 271.0M
- DMAC 321.5M
- IPO Year
- NCZ N/A
- DMAC N/A
- Fundamental
- Price
- NCZ $13.67
- DMAC $5.95
- Analyst Decision
- NCZ
- DMAC Strong Buy
- Analyst Count
- NCZ 0
- DMAC 4
- Target Price
- NCZ N/A
- DMAC $15.50
- AVG Volume (30 Days)
- NCZ 533.0K
- DMAC 315.3K
- Earning Date
- NCZ 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- NCZ 12.16%
- DMAC N/A
- EPS Growth
- NCZ N/A
- DMAC N/A
- EPS
- NCZ N/A
- DMAC N/A
- Revenue
- NCZ N/A
- DMAC N/A
- Revenue This Year
- NCZ N/A
- DMAC N/A
- Revenue Next Year
- NCZ N/A
- DMAC N/A
- P/E Ratio
- NCZ N/A
- DMAC N/A
- Revenue Growth
- NCZ N/A
- DMAC N/A
- 52 Week Low
- NCZ $2.50
- DMAC $3.19
- 52 Week High
- NCZ $3.15
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- NCZ 41.25
- DMAC 42.03
- Support Level
- NCZ $13.79
- DMAC $5.26
- Resistance Level
- NCZ $14.36
- DMAC $6.47
- Average True Range (ATR)
- NCZ 0.23
- DMAC 0.41
- MACD
- NCZ -0.05
- DMAC -0.10
- Stochastic Oscillator
- NCZ 6.41
- DMAC 36.50
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.